THE ANTIBODY‐DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT‐402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI‐LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION. (12th June 2019)